Personalized & Point-of-Care Testing in the Respiratory Diseases Diagnostic Market According to a newly published market research report by 24LifeSciences, global respiratory diseases diagnostic testing market was valued at USD 1.82 billion in 2026 and is projected to reach USD 3.05 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.7% during the forecast period. Respiratory diseases diagnostic testing encompasses a comprehensive suite of procedures and tools used to detect, diagnose, and monitor conditions affecting the lungs and pulmonary system. These critical tests include imaging studies like chest X-rays and CT scans, respiratory function measurements such as spirometry, blood gas analyses to assess oxygen and carbon dioxide levels, and advanced molecular tests for pathogen identification. The growing prevalence of respiratory conditions, heightened post-pandemic awareness, and significant technological innovation are key factors driving substantial market expansion. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9415/respiratory-diseases-diagnostic-testing-market